Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More
CIPLA | DR. REDDYS LAB | CIPLA/ DR. REDDYS LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.2 | 40.4 | 84.6% | View Chart |
P/BV | x | 4.8 | 5.5 | 87.4% | View Chart |
Dividend Yield | % | 0.4 | 0.5 | 88.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
DR. REDDYS LAB Mar-20 |
CIPLA/ DR. REDDYS LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 3,363 | 17.4% | |
Low | Rs | 357 | 2,352 | 15.2% | |
Sales per share (Unadj.) | Rs | 207.0 | 1,054.2 | 19.6% | |
Earnings per share (Unadj.) | Rs | 18.6 | 121.9 | 15.3% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 190.2 | 17.4% | |
Dividends per share (Unadj.) | Rs | 4.00 | 25.00 | 16.0% | |
Dividend yield (eoy) | % | 0.8 | 0.9 | 97.0% | |
Book value per share (Unadj.) | Rs | 195.5 | 938.7 | 20.8% | |
Shares outstanding (eoy) | m | 806.35 | 166.17 | 485.3% | |
Bonus/Rights/Conversions | ESOS | ESOP | - | ||
Price / Sales ratio | x | 2.3 | 2.7 | 84.0% | |
Avg P/E ratio | x | 25.3 | 23.4 | 108.1% | |
P/CF ratio (eoy) | x | 14.2 | 15.0 | 94.6% | |
Price / Book Value ratio | x | 2.4 | 3.0 | 79.2% | |
Dividend payout | % | 21.5 | 20.5 | 104.9% | |
Avg Mkt Cap | Rs m | 379,912 | 474,831 | 80.0% | |
No. of employees | `000 | 25.8 | 21.7 | 119.4% | |
Total wages/salary | Rs m | 30,270 | 33,802 | 89.6% | |
Avg. sales/employee | Rs Th | 6,459.6 | 8,091.0 | 79.8% | |
Avg. wages/employee | Rs Th | 1,171.2 | 1,561.3 | 75.0% | |
Avg. net profit/employee | Rs Th | 580.2 | 935.8 | 62.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 175,170 | 95.3% | |
Other income | Rs m | 3,442 | 6,206 | 55.5% | |
Total revenues | Rs m | 170,391 | 181,376 | 93.9% | |
Gross profit | Rs m | 32,060 | 24,421 | 131.3% | |
Depreciation | Rs m | 11,747 | 11,348 | 103.5% | |
Interest | Rs m | 1,974 | 983 | 200.8% | |
Profit before tax | Rs m | 21,782 | 18,296 | 119.1% | |
Minority Interest | Rs m | -475 | 0 | - | |
Prior Period Items | Rs m | 0 | 561 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6,312 | -1,403 | -449.9% | |
Profit after tax | Rs m | 14,995 | 20,260 | 74.0% | |
Gross profit margin | % | 19.2 | 13.9 | 137.7% | |
Effective tax rate | % | 29.0 | -7.7 | -377.9% | |
Net profit margin | % | 9.0 | 11.6 | 77.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 125,991 | 92.9% | |
Current liabilities | Rs m | 43,931 | 72,141 | 60.9% | |
Net working cap to sales | % | 43.8 | 30.7 | 142.4% | |
Current ratio | x | 2.7 | 1.7 | 152.5% | |
Inventory Days | Days | 96 | 73 | 131.0% | |
Debtors Days | Days | 85 | 105 | 81.2% | |
Net fixed assets | Rs m | 107,424 | 83,854 | 128.1% | |
Share capital | Rs m | 1,613 | 831 | 194.0% | |
"Free" reserves | Rs m | 156,018 | 155,157 | 100.6% | |
Net worth | Rs m | 157,630 | 155,988 | 101.1% | |
Long term debt | Rs m | 23,693 | 1,304 | 1,816.9% | |
Total assets | Rs m | 236,626 | 232,253 | 101.9% | |
Interest coverage | x | 12.0 | 19.6 | 61.4% | |
Debt to equity ratio | x | 0.2 | 0 | 1,798.0% | |
Sales to assets ratio | x | 0.7 | 0.8 | 93.5% | |
Return on assets | % | 7.2 | 9.1 | 78.4% | |
Return on equity | % | 9.5 | 13.0 | 73.2% | |
Return on capital | % | 12.8 | 12.6 | 101.8% | |
Exports to sales | % | 33.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 55,175 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 56,036 | 84,193 | 66.6% | |
Fx outflow | Rs m | 6,764 | 39,616 | 17.1% | |
Net fx | Rs m | 49,272 | 44,577 | 110.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | 29,841 | 102.8% | |
From Investments | Rs m | 1,040 | -4,923 | -21.1% | |
From Financial Activity | Rs m | -29,488 | -25,159 | 117.2% | |
Net Cashflow | Rs m | 2,340 | -266 | -879.8% |
Indian Promoters | % | 16.0 | 25.5 | 62.7% | |
Foreign collaborators | % | 20.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 12.2 | 5.4 | 225.9% | |
FIIs | % | 23.7 | 35.3 | 67.1% | |
ADR/GDR | % | 1.1 | 18.5 | 5.9% | |
Free float | % | 26.2 | 15.3 | 171.2% | |
Shareholders | 161,166 | 75,885 | 212.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: ALEMBIC AUROBINDO PHARMA PIRAMAL ENTERPRISES FDC SUN PHARMA
Compare CIPLA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.
For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
In this video I tell you the three Nifty ETFs I think are the best.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More